

Newborn Screening
The assays allow the quantitative determination of relevant analytes from dried blood samples as part of the newborn screening procedure with flow injection analysis and tandem mass spectrometry (FIA-MS/MS).
The aim of newborn screening is to detect congenital metabolic disorders at an early stage – before they can lead to health problems.
MassScreen® Amino Acids, Acylcarnitines EXTENDED from Dried Blood
- 62 analytes in one run, including adenosine and 2'-deoxyadenosine
- IVDR certified
- No derivatisation necessary
- No analytical column required
- Matrix-based controls at three concentration levels
- Linearity sets for determining the upper MS/MS measuring range
The new extended assays allow the simultaneous determination of 62 analytes, thereby increasing the number of metabolic diseases that can be screened for in a single run.
Validated in accordance with IVDR, the assays meet stringent regulatory requirements. A comprehensive panel of internal standards is designed to support precise and consistent measurements. The upper end of the measuring range of the MS/MS system can be determined using the new linearity sets. In addition, the newly introduced three-point controls are developed to support precision and reproducibility.
There are two kit options available with or without adenosine (Ado) and 2'-deoxyadenosine (dAdo) measurement. Each of these options are available in two versions with 96 well plates or 96 well filter plates.
Order no. | Plates | Determination of Ado/dAdo |
57075 | 96 well plates | No |
57075-F | 96 well filter plates | No |
57075-ADO | 96 well plates | Yes |
57075-F-ADO | 96 well filter plates | Yes |
MassChrom® Amino Acids and Acylcarnitines from Dried Blood
- Assay with and without derivatisation available
- 26 analytes in a single run
- Additionally succinylacetone (SUAC) when using the Upgrade Set
- No analytical column required
- Screening for many metabolic disorders in a single run
- Matrix-based controls
The assays are available in two versions: one with and one without derivatisation (= butylation) of the analytes. An upgrade set for the determination of succinylacetone is available for both versions. Succinylacetone is a primary marker for the detection of Tyrosinemia Type I in newborns. In many countries, it is part of newborn screening programs.
Assay with derivatisation
Derivatisation (= butylation) of the analytes offers high sensitivity and low interference. Sample preparation is done utilizing 96 well plates. During subsequent MS/MS analysis, either Neutral Loss Scan or Multiple Reaction Monitoring (MRM) is used for amino acids and succinylacetone, and Parent Ion Scan is used for acylcarnitines.
Assay without derivatisation
Without derivatisation of the analytes, sample preparation is simpler and faster. Preparation is carried out either in 96 well plates or in 96 well filter plates. During subsequent MS/MS analysis, Multiple Reaction Monitoring (MRM) is used for all analytes.
Order No. | Information |
57000 | Kit with 96 well plates |
57000/F | Kit with 96 well filter plates |
57111 | Succinylacetone Upgrade Set for kit 57000 |
57111/F | Succinylacetone Upgrade Set for kit 57000/F |
Download brochure



